A late-stage trial will begin later this year in South Africa to test the effectiveness of an HIV vaccine that has shown promise in earlier trials, according to the National Institutes of Health.
Results from an ongoing preliminary trial in South Africa and a previous late-stage trial in Thailand suggest the new vaccine may provide lasting protection against the human immunodeficiency virus (HIV), which causes AIDS.
"It is a follow up trial to the only trial that has shown partial efficacy," said Dr. Larry Corey, president and director emeritus of Fred Hutchinson Cancer Research Center and principal investigator . . .
